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Abstract
The inhibitory effects of 13-epimeric estrones, D-secooxime and D-secoalcohol estrone
compounds on human placental 17b-hydroxysteroid dehydrogenase type 1 isozyme (17b-
HSD1) were investigated. The transformation of estrone to 17b-estradiol was studied by an
in vitro radiosubstrate incubation method. 13a-Estrone inhibited the enzyme activity effectively
with an IC50 value of 1.2 mM, which indicates that enzyme affinity is similar to that of the natural
estrone substrate. The 13b derivatives and the compounds bearing a 3-hydroxy group
generally exerted stronger inhibition than the 13a and 3-ether counterparts. The 3-hydroxy-
13b-D-secoalcohol and the 3-hydroxy-13a-D-secooxime displayed an outstanding cofactor
dependence, i.e. more efficient inhibition in the presence of NADH than NADPH. The 3-hydroxy-
13b-D-secooxime has an IC50 value of 0.070 mM and is one of the most effective 17b-HSD1
inhibitors reported to date in the literature.
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Introduction
The human 17b-hydroxysteroid dehydrogenase type 1 (17b-
HSD1, EC 1.1.1.62) protein is comprised of 328 amino acids and
exists as a cytosolic functional homodimer with a subunit
molecular mass of 34 950 Da1,2. Amino acid sequence alignments
and homology studies have revealed that it belongs to the short-
chain dehydrogenase/reductase (SDR) superfamily. 17b-HSD1 is
a pluripotent enzyme in terms of substrate, cofactor, and the
oxidative and reductive direction of the 17b-hydroxy-17-oxo
interconversion. This isozyme is capable of the 3b-hydroxy
reduction of substrates bound in reverse mode3.
Under in vivo conditions, as in living cells, however, the
isoenzyme functions unidirectionally4–6 and predominantly cata-
lyze the NADPH-promoted stereospecific reduction of estrone
(1a) to 17b-estradiol (E2) (Scheme 1), the final hormone-
activating process in estrogen biosynthesis5,7. The highest
expression and activity of the isozyme may be observed in the
female steroidogenic reproductive tissues, such as the ovaries and
the placenta8. This isozyme makes a major contribution to the
general gonadal supply and to the circulating level of E2 in the
blood. 17b-HSD1 is also expressed and active in peripheral
tissues, where it regulates the intracellular accumulation of E2
and consequently the intracrine estrogen effect3,9. 17b-HSD1
has been reported to be responsible for the intracellular overpro-
duction of E2 in various neoplasms. The pathophysiological
accumulation of E2 then contributes to the development and
progression of estrogen-dependent forms of endometriosis, breast
cancer and ovarian cancer. The inhibition of 17b-HSD1 with
suitable pharmacons may suppress both the systemic and the local
or in situ synthesis of E2. The evoked pre-receptorial anti-
hormonal effect offers a suitable option for the therapy of
estrogen-dependent diseases. 17b-HSD1 inhibitors may serve as
interesting drug targets of anti-estrogen therapy2,10.
Numerous earlier studies have demonstrated that various
estrone and 17b-estradiol derivatives inhibit 17b-HSD1 activity
effectively2,9,11,12. Inhibitor design based on the estrane core is
nonetheless limited, because they must be devoid of estrogenic
activity13–17.
Certain structural modifications of the estrane skeleton, such
as the opening of ring D or inversion of the configuration at C-13,
may lead to the complete loss of hormonal activity18–20. We
recently described the synthesis and in vitro investigation of the
17b-HSD1-inhibitory activities of C-13 epimeric 17-(triazolyl-
methyl)carboxamido D-secoestrone derivatives bearing ether
protecting groups on C-321. The nature of the functional groups
on C-3 and/or C-17 and the orientation of the angular methyl
group influence the enzyme inhibitory potential substantially.
Certain 3-methoxy-13b-D-secoestrones and one 3-benzyloxy-13a
derivative displayed low micromolar 17b-HSD1 inhibitory
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potentials. This biological activity of D-secoestrones was a novel
finding and alludes to the design of hormonally inactive 17b-
HSD1 inhibitors on these scaffolds in both the 13a- and 13b-
estrone series.
We recently described the halogenation of ring A of 13a-
estrone with different protecting groups at position 322. The
halogen derivatives were designed on the basis of the literature
analogy of similarly halogenated 13b-estrones as nanomolar
inhibitors of 17b-HSD1. The inhibitory potential of the 13a-
compounds depended markedly on the nature and the size of the
protecting group on the phenolic OH function. The presence of H
or methyl was advantageous relative to the more bulky benzyl
group. Effective 13a-estrones such as these 17b-HSD1 inhibitors
had not been published previously.
We now report an investigation of the inhibitory potentials of
C-13 epimeric 3-OH and 3-ether estrone derivatives bearing an
intact or seco ring D towards human placental 17b-HSD1. In vitro
inhibition tests were performed with both the cofactors NADPH
and NADH that are regularly applied in these assays.
Materials and methods
Chemistry
Compounds 1a and 1c were purchased from Sigma (St. Louis,
MO) and 1b from Steraloids (Newport, RI). 13a-Derivatives (2b
and 2c) were obtained by the epimerization of 1b or 1c using the
literature methods18,S3. 13a-Estrone (1a) was obtained by
debenzylation of 1bS3. The experimental details for the chemical
synthesis and data on the compounds (3–6) are presented in the
Supplemental Information.
Determination of 17b-HSD1 activity and its inhibition in
the human placenta cytosol
Radioactive [6,7-3H(N)]estrone, S.A.¼ 50 Ci/mmol, was pur-
chased from American Radiolabeled Chemicals (St. Louis,
MO). Non-radioactive estrone (1a) and E2 standards, NADH
and NADPH cofactors, other chemicals and solvents of analytical
grade purity were purchased from Sigma (St. Louis, MO) or Fluka
(Buchs, Switzerland). Kieselgel-G TLC layers (Si 254 F, 0.25 mm
thick) were from Merck (Darmstadt, Germany). Human term
placenta specimens were collected and used with the ethical
approval of the Institutional Human Investigation Review Board.
The inhibitory effects of the newly synthesized compounds on
the 17b-HSD1 activity were investigated via the conversion of 1a
to E2 in vitro. Human placental cytosol served as a source for the
isozyme21,23. Human term placenta specimens were combined
and homogenized with an Ultra-Turrax in 0.1 M HEPES buffer
(pH¼ 7.3) containing 1 mM EDTA and 1 mM dithiotreitol and the
cytosol was obtained by fractionated centrifugation. Substrate 1a
(1mM) with its tritiated tracer (250 000 dpm) was added to the
incubator in 10 mL of 25 v/v% propylene glycol in HEPES buffer
solution, whereas the test compounds were applied in 10 mL of
dimethyl sulfoxide solution. (These organic solvent contents in the
200mL final volume of the HEPES buffer incubation medium did
not reduce the enzyme activity substantially.) The cofactor, either
NADH or NADPH, was used in an excess concentration of
100mM. The enzymatic reaction was started by the addition of the
cytosol aliquots. Incubation was carried out at 37 C for 2.5 min
and was then stopped by the addition of ethyl acetate and freezing.
After extraction with ethyl acetate, unlabelled carriers of 1a and
the product E2 were added to the samples. The two steroids were
separated by TLC with the solvent system dichloromethane/
diisopropyl ether/ethyl acetate (70:15:15 v/v) and UV spots were
used to trace the separated steroids. Spots were cut out and the
radioactivity of the E2 formed and the 1a remaining was
measured by means of liquid scintillation counting. 17b-HSD1
activity was calculated from the radioactivity of the E2 with
correction for the recovery.
The assays were performed in triplicate for determination of
the percentages of relative inhibited conversions at a final
inhibitor concentration of 10mM, and the standard deviations
(SDs) were also calculated. IC50 values (the inhibitor concentra-
tion that decreases the enzyme activity to 50%) were determined
for the most effective and other selected test compounds. In these
cases, conversions were measured at 10–15 different concentra-
tions in the appropriate interval 0.001–50 mM. IC50 results were
calculated by using unweighted iterative least squares logistic
curve fitting by means of the ‘‘absolute IC50 calculation’’
function of the GraphPad Prism 4.0 (GraphPad Software, Inc.,
San Diego, CA). The IC50 of unlabelled estrone (1a) was
measured as reference. The relative inhibitory potentials (RIPs) of
the test compounds were calculated by using reference IC50 data
measured with the corresponding cofactor: RIP¼ IC50 of test
compound/IC50 of unlabelled estrone (1a).
With the selected incubation parameters, the enzyme reaction
satisfied the conditions of the initial velocity measurements. The
conversions in the non-inhibited control incubates reached similar
rates (10–13%) with both cofactors, and the product formation
was proportional to the enzyme concentration and the incubation
duration. The 1mM substrate was a saturation concentration in the
presence of NADPH, whereas it was on the declining proportional
phase with NADH (data not shown).
Results and discussion
17b-HSD1 inhibition
The steroid ligand binding site of 17b-HSD124,25 has been
described as a hydrophobic tunnel with polar residues at each end.
The surface of the tunnel is complementary to the C18 steroidal
scaffold and ensures selectivity towards estrogenic substrates26.
At the C-terminal recognition end, hydrophilic amino acids form
hydrogen-bonds to the 3-hydroxy group of the substrate27,28.
These interactions fix the substrate and its C-17 oxo into an
appropriate orientation for the catalytic transformation7,24,29, but
they have been found not to be essential for the binding, and they
may even establish a catalytically unfavourable position for non-
cognate substrates30. Residues of the N-terminal catalytic end
form triangular hydrogen-bond contacts with the C-17 carbonyl
Scheme 1. Stereospecific reduction of estrone
(1a) to 17b-estradiol (E2) by 17b-HSD1.
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oxygen and facilitate a charge-equalizing proton transfer follow-
ing the hydride donation from the nicotinamide moiety of the
cofactor6,24,31.
NADPH and NADH bind in the same extended conformation
to 17b-HSD1, pointing towards the active site with their
nicotinamide ring27,30, and both cofactors are able to promote
the stereospecific reduction of the C-17 carbonyl of the substrate.
Despite these resemblances, NADPH and NADH are not inter-
changeable as cofactors of 17b-HSD1. Their different interactions
and the different ground and transition state structures32 suggest
that different modes of binding exist for the phosphorylated and
the unphosphorylated cofactors. Binding differences induce
different conformational changes in the cofactor binding cleft,
which extends towards the catalytic cleft of the active centre in its
close proximity33.
Estrane-based inhibitors are assumed to occupy the substrate-
binding site of 17b-HSD1, and are able to form other contacts to
the enzyme than substrate molecules2,9,12. These interactions may
improve the binding affinity and modulate the inhibitory poten-
tial34. The complexities of the interaction mechanisms of 17b-
HSD1 have the result that relatively small changes in the shape of
the steroid substrate or inhibitor ligand, and/or in the protein
conformation induced by the cofactor or by other modulators can
significantly affect the binding and catalytic arrangements, and
consequently the binding affinity, the inhibitor potential and the
selectivity.
Natural estrone possesses a tetracyclic steroidal framework
with trans junctions of rings B/C and C/D. The other character-
istics of this classical steroid are the typical conformations of
rings C (chair) and D (strongly restricted). The rigid structure of
estrone contains two oxygen functionalities with well-defined
distances, which are crucial in the binding of estrone or estradiol
to its nuclear hormone receptors. In contrast with the natural 13b
compound, the 13 epimer has a quasi-equatorial angular methyl
group, a cis junction of rings C/D and a ring D that is directed to
the b side18. Poirier et al. reported the impact of inversion of the
configuration at C-13 and/or C-17 of estradiols on their estrogenic
activity20. They concluded that 13 epimers have low relative
binding affinity for estrogen receptor alpha and have no signifi-
cant uterotropic activity. Accordingly, inversion at C-13 in the
estrane skeleton could be a correct strategy in the design of
estrone-based anticancer agents lacking estrogenic activity.
In this work, we determined the in vitro inhibitory potencies on
human placental 17b-HSD1 of the 3-hydroxy and the 3-ether
derivatives of 13a- and 13b-estrones (1, 2) and D-secoestrones
(3–6) (Figure 1) in the presence of NADPH or NADH.
The reference IC50 data determined for unlabelled estrone (1a)
were found to be 2.0 mM in the presence of NADH and 0.63 mM
when NADPH was applied as cofactor (Table 1). These IC50
results are similar to those of the earlier published results by other
authors (for placental 17b-HSD1)5,23,35–37.
13a-Estrone (2a) proved here to be a potent inhibitor,
displaying low micromolar IC50 values similar to those of the
unlabelled reference estrone (1a). The 13a epimer (2a) of the
natural estrogenic prehormone 1a has long been known38, but its
inhibitory properties against the 17b-HSD1 activity have not been
reported so far. Recently, 17b-HSD1 inhibition of 16-substituted
derivatives of the 13a-estradiol has been investigated39.
As concerns the inhibitory activities of the test compounds
bearing an intact ring D (1a–c and 2a–c), the nature of the
substituent on C-3 was the determining factor. Similar to the
earlier established relationships22, the presence of the phenolic
OH or the small methyl ether function was more advantageous
than the bulky apolar benzyl group. The 13a methyl ether 2c
displayed a lower range activity than that of its 13b counterpart
(1c). Our results tend to confirm the earlier observations22 that the
hydrogen-bonds of a phenolic OH function in this position might
be beneficial, but not absolutely necessary for efficient inhibition.
As concerns the secoestrones, the two epimeric D-secoalco-
hols (3a and 4a) display IC50 values in the low or submicromolar
range. Of the 3-methyl ethers of the secoalcohol (3c and 4c), only
the 13b counterpart (3c) was proved effective, but with higher
IC50 value than that of its 3-OH derivative (3a). The epimeric 3-
hydroxy-D-secooximes (5a and 6a) displayed noteworthy inhibi-
tory properties and C-13 chirality dependence. 5a was found to be
highly potent in the presence of either NADPH or NADH, with
IC50 values of 0.070 mM and 0.077mM, respectively. The 13a
counterpart (6a) was effective only when NADH was used as a
cofactor (IC50¼ 0.058mM). The oxime epimer pairs of 5a and 6a
displayed a large difference, demonstrating inhibition around 400-
fold stronger of the 13b than that of the 13a epimer in the
presence of NADPH, whereas they exerted similar effect with
NADH.
The inhibitory data of the D-seco compounds reveal that the
nature of the 3 substituent has a crucial influence on the activities.
Of the epimeric oxime ethers (5b, c and 6b, c), only one 13b
epimer (5c), bearing a small methyl group on the phenolic OH
function, exerted substantial inhibitory effect, which was more
pronounced than that observed for the 13b secoalcohol 3-methyl
ether (3c).
Molecular mechanic and semi-empirical energy minimizations
of the most potent 3-OH derivatives (2a–6a) were performed to
demonstrate their structural features and differences (Figure 2).
Figure 2 reveals that the epimerization of C-13 modifies the ring
D region considerably. Functional groups in this region (carbonyl,
hydroxymethyl or oxime) display alterations in position, direction
and distance from those of 3-OH in the epimer pairs. Despite
these structural differences, 13a-estrone (2a) binds to 17b-HSD1
with similar affinity as for the cognate substrate. As concerns the
D-secoestrones (3a–6a), the 13b compounds (3a and 5a) possess
an axial angular methyl group and an equatorial functional group
on C-13. In contrast with the 13b derivatives, the angular methyl
group of 13a-D-secoestrones (4a and 6a) has an equatorial
orientation, and the oxime or primary alcoholic function is
axial40. The oxime function has a double bond with E or Z
orientation, but the primary alcoholic group can rotate freely. The
difference in the inhibitory activities of the oximes and alcohols
may therefore reflect the differences in the nature and the position
of the C-17 functional groups. It may be postulated that in 5a or
6a, this oxime side-chain may take up an appropriate position to
form strong hydrophilic interactions or hydrogen-bonds to certain
amino acids of the enzyme, and these interactions may cause the
high affinity and outstanding inhibitory potentials observed for
the oximes. The noteworthy effectiveness of the oximes may be
ascribed to the capability of the oxime function to form strong
interactions with certain amino acid residues of the target
proteins. Further investigations might identify the amino acid
residues which are involved in these interactions.
Cofactor dependence
The 17b-HSD1 inhibition results of the test compounds demon-
strate the influence of the cofactor partner. 13b-Estrone 3-methyl
ether (1c) exerted a five-fold stronger inhibition in the presence of
the phosphorylated cofactor. 13a-Estrone (2a) and its methyl
ether (2c) displayed similar IC50 values with the two cofactors,
but the RIP data demonstrated a 2–3-fold higher potential with
NADH in comparison with the reference 1a. The cofactor
dependence was more pronounced among the D-seco compounds.
The IC50 values were found to be 2–3-fold lower, indicating a 3–
7-fold higher inhibition effect in terms of the RIP measured with
NADH. The difference was further enhanced for the 13b epimer
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of the D-secoalcohol (3a), which exerted an 8–9-fold more
effective inhibition with NADH according to the IC50 data, and a
25-fold stronger effect in the sense of the RIP values.
The 13a epimer of the D-secooxime (6a) displayed an
outstanding cofactor dependence. This compound exerted only
weak inhibition with NADPH, but it was highly effective in the
presence of NADH. The difference between the IC50 values was
more than 500-fold, whereas the RIP ratio exceeded 1200.
Since the two secooxime epimers, 5a and 6a, differ only in the
position of the angular methyl and the oxime function, the
orientation of this part of the molecule seems to be favourable in
the NADH complex of the enzyme for both the 13a and the 13b
epimers (6a and 5a), but only for 5a in the NADPH complex.
Effective binding of the 13a counterpart (6a) is possibly
prevented by the increased specificity towards 13b compounds
of the NADPH complex. The side chain at C-13 in 6a may be
directed into an unfavoured position, which cannot be modified
because of the limited flexibility of the oxime function caused by
its double bond. The related alcohols 3a and 4a display similar
inhibitory potencies, irrespective of the orientation of the angular
methyl group, as the shorter and more rotatable side chain may
find its optimum position either in the NADH or in the NADPH
complexed protein.
Other SDR enzymes feature NADH for the catalytic process
and early studies annotated this cofactor to the reductive direction
of 17b-HSD130,41,42. Numerous in vitro inhibition tests have been
performed with supplementation of the unphosphorylated cofac-
tor too. Higher affinity for 17b-HSD1 of NADPH over
NADH5,29,43,44 and considerations of the abundance and meta-
bolic roles of nicotinamide cofactors4,45,46 have made it evident
that NADPH might be the prevalent partner of 17b-HSD1 in its
in vivo function, in the 1a–E2 conversion4,46.
Only a few data are to be found in the literature as concerns the
direct comparison of inhibitory potencies with NADPH
versus NADH. The hybrid inhibitor EM-1745, in which an
unphosphorylated cofactor-mimicking moiety was coupled to the
estradiol core, and which was therefore planned to act on both the
active centre and the cofactor binding site of the enzyme, proved
to be a weaker inhibitor of 17b-HSD1 when NADPH was used as
cofactor rather than NADH47. This difference, however, was
explained specifically that the adenosine moiety of EM-1745 does
not bind the cofactor-binding site of 17b-HSD1 as strongly as the
phosphorylated adenosine moiety of NADPH, and thus the
bisubstrate inhibitor EM-1745 (without a phosphate group)
cannot compete efficient enough against the cofactor NADPH.
Our D-seco compounds 3a and 6a do not possess a cofactor-
mimicking moiety, but they display large differences in inhibitory
potential measured in the presence of NADPH or NADH.
These inhibition results indicate that the apparent in vitro
potentials obtained with the two cofactors may differ substantially
for certain compounds. Data on NADPH and NADH are not
interchangeable and their direct comparison (e.g. in one table48) is
not advised. The literature data must be reviewed with special
attention to the cofactor supplementation, the screening systems49
should be specified precisely, and NADPH should be preferred
instead of NADH in cell-free in vitro inhibitor tests. The influence
of cofactors might be an explanation for the altered, occasionally
disappointingly decreased inhibition potentials obtained in cellu-
lar 17b-HSD1 inhibition assays performed following promising
cell-free screening tests with NADH50. Data measured in the
presence of NADH must be evaluated with caution in inhibitor
optimization and in lead selection. NADH results are less relevant
to the potential in vivo effect, but could be valuable in facilitating
the understanding of the mechanism of catalysis and the inhibition
of 17b-HSD1.
17b-HSD1 inhibition and antiproliferative effects
The synthesis and in vitro investigation of the antiproliferative
potentials of the D-secoestrone derivatives tested here for their
Figure 1. Structural formulae of the test
compounds (1–6).
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Table 1. Inhibition results on 17b-HSD1.
IC50±SD (mM) and RIP or relative conversion at 10mM ± SD (%)
Compd. Structure NADPH NADH
1a
HO
HH
H
O
IC50¼ 0.63 ± 0.11
RIP¼ 1.0
IC50¼ 2.0 ± 0.18
RIP¼ 1.0
1b
BnO
HH
H
O
52 ± 2 52 ± 5
1c
MeO
HH
H
O
IC50¼ 0.77 ± 0.29
RIP¼ 1.2
IC50¼ 4.2 ± 1.6
RIP¼ 2.1
2a
HO
HH
H
O
IC50¼ 1.2 ± 0.2
RIP¼ 1.7
IC50¼ 1.1 ± 0.3
RIP¼ 0.59
2b
BnO
HH
H
O
55 ± 3 65 ± 10
2c
MeO
HH
H
O
IC50¼ 5.5 ± 1.5
RIP¼ 8.8
IC50¼ 7.5 ± 2.5
RIP¼ 3.7
3a
CH2OH
HO
HH
H
IC50¼ 3.4 ± 1.4
RIP¼ 5.4
IC50¼ 0.41 ± 0.24
RIP¼ 0.21
3b 76 ± 7 70 ± 4
(continued )
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Table 1. Continued
IC50±SD (mM) and RIP or relative conversion at 10mM ± SD (%)
Compd. Structure NADPH NADH
CH2OH
BnO
HH
H
3c
CH2OH
MeO
HH
H
IC50¼ 9.0 ± 1.7
RIP¼ 14.3
IC50¼ 5.5 ± 1.9
RIP¼ 2.7
4a
CH2OH
HO
HH
H
IC50¼ 3.7 ± 1.3
RIP¼ 5.8
IC50¼ 1.7 ± 0.3
RIP¼ 0.85
4b
CH2OH
BnO
HH
H
84 ± 6 83 ± 7
4c
CH2OH
MeO
HH
H
66 ± 10 67 ± 6
5a
CH
HO
HH
H
N OH
IC50¼ 0.070 ± 0.027
RIP¼ 0.11
IC50¼ 0.077 ± 0.036
RIP¼ 0.039
5b
BnO
HH
H
CH N OH
76 ± 10 82 ± 0.4
5c
MeO
HH
H
CH N OH
IC50¼ 3.1 ± 1.7
RIP¼ 4.9
IC50¼ 1.9 ± 0.8
RIP¼ 0.93
6a
HO
HH
H
CH N OH
IC50¼ 30 ± 7
RIP¼ 48
IC50¼ 0.058 ± 0.044
RIP¼ 0.029
(continued )
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17b-HSD1 inhibitory properties have recently been reported51,52.
Our potential anticancer agents were designed on the hormonally
inactive D-seco- and/or 13a-estrone core. 3-Benzyloxy-D-secoes-
trone alcohol (3b), the first D-secoestrone in the literature,
displays substantial in vitro antiproliferative effects against a
number of human reproductive cancer cell lines with good tumour
selectivity51. The debenzylated secoalcohol (3a) containing a
3-phenolic group did not inhibit tumour cell growth markedly.
These results led to further D-secoestrone derivatives as potential
antitumour agents. 17-Oxime derivatives of the potent secoalco-
hol (3b) were synthesized and diversified at several sites of the
molecule: 3-ethers (5b,c and 6b,c) or 3-hydroxy derivatives
(5a and 6a) were investigated in both the 13b- and the 13a-
estrone series52. None of the 13a epimers (6) or the 3-hydroxy
derivatives (5a) exerted substantial antiproliferative activities, but
the 13b-D-secoestrone-3-ethers (5b,c) proved to be effective
against various cell lines (HeLa, A2780, A431 and MCF-7) with
IC50 values in the low mM range. Tests were performed on cell
lines with diverse steroidogenic and steroid responsive properties,
and the results suggested that the cytotoxic effect is most probably
independent of the estrogen hormonal mechanisms, and the
17b-HSD1 inhibition among them.
The literature reveals that it is possible to combine direct
cytostatic activity with 17b-HSD1-inhibitory potential, resulting
in dual action against estrogen-dependent tumours. It is therefore
reasonable to evaluate our present results in this sense too
(Figure 3). Depending on the nature of the substituent at C-3, 13b-
methyl-D-secoestrone oxime (5) is able to exert different
Figure 2. Molecular structures of compounds
1a–6a.
IC50±SD (mM) and RIP or relative conversion at 10mM ± SD (%)
Compd. Structure NADPH NADH
6b
BnO
HH
H
CH N OH
90 ± 17 77 ± 5
6c
MeO
HH
H
CH N OH
IC50¼ 21 ± 7
RIP¼ 34
IC50¼ 24 ± 10
RIP¼ 12
Relative conversions (control incubation with no inhibition is 100%) measured in the presence of 10mM of the compound tested. IC50: The inhibitor
concentration that decreases the enzyme activity to 50%. RIP: relative inhibition potency compared to reference E1. SD: standard deviation (for
relative conversion n¼ 3).
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important biological activities: bearing an unsubstituted 3-OH
(5a), which belongs to the highly potent 17b-HSD1 inhibitors
with unmarked antiproliferative action on the examined cell lines.
Compound 5b, possessing a bulky apolar benzyl protecting group,
substantially inhibits the growth of certain cell lines, but does not
influence the estrone–estradiol conversion catalysed by 17b-
HSD1. The methyl ether (5c) behaves dually by inhibiting both
the cell growth and 17b-HSD1 as enzyme. The same tendency
appears in the results of the antiproliferative and 17b-HSD1
inhibitory measurements as concerns 13b-methyl-D-secoestrone
alcohol (3), but it can be stated that the biological activities of the
secooximes are more pronounced than those of their alcoholic
counterparts. Compound 5a or 5b, however, is a selective 17b-
HSD1 inhibitor or an antiproliferative agent respectively, in this
comparison.
The 3-methyl ether of D-secoestrone oxime (5c) may be
considered as a compound with a dual mode of action, as it
displays a noteworthy direct antiproliferative effect against a
number of human reproductive cancer cell lines (independently of
their 17b-HSD1 or ER status), and exerts substantial inhibitory
potential against 17b-HSD1. Since 17b-HSD1 inhibition is a
promising approach for the treatment of estrogen-dependent
tumours, it decreases the level of estradiol in the tumour cells, a
compound with a dual mode of action may be superior to simple
17b-HSD1 inhibitors.
Conclusions
17b-HSD1 has been studied for more than half a century, but none
of its inhibitor candidates have yet reached clinical trials for the
treatment of estrogen-dependent diseases. Since breast cancer is
the most common cancer among women in the Western world,
further intensive research efforts are demanded. In order to
develop potent and selective 17b-HSD1 inhibitors, a profound
understanding of the enzymatic mechanisms and the structure–
function relationships is essential.
The present study has revealed that 13a-estrone (2a) and some
D-secoestrone derivatives (3a–6a, 3c and 5c), might be promising
inhibitors. The very low in vitro IC50 of 5a indicates that this
compound is one of the most effective 17b-HSD1 inhibitors ever
reported. Its 3-methyl ether (5c) may be regarded as the first
published D-secoestrone that exerts dual independent pre-
receptorial antihormonal and antiproliferative effects. Further
derivatization of the promising 13a-estrone and D-secoestrone
oxime scaffold may lead to drug candidates that possess a
beneficial combination of direct cytostatic and endocrine dis-
ruptor behaviour. The different in vitro inhibitory potentials
observed for the C-13 epimer pairs, with the cofactor NADH
instead of NADPH, are interesting findings. Additional
investigations with the aim of elucidating the binding mechanisms
may provide new data clarifying the structure–function relation-
ships of 17b-HSD1.
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